

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE
THERAPEUTIC STUDIES ONLY (TXCA=Y)
88% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2018 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2018 Accrual</u>	<u>Projected Increase <Decrease> from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase <Decrease> from Base</u>
BREAST	1558	791	51%	902	-655	900	-658
ERLYTX	76	344	453%	392	316	455	379
GI	476	101	21%	115	-360	130	-346
GU	450	317	70%	361	-88	351	-99
GYN	57	0	0%	0	-57	0	-57
LEUK	150	117	78%	133	-16	121	-29
LUNG	524	215	41%	245	-278	252	-272
LYMPH	172	25	15%	28	-143	26	-146
MELAN	55	85	155%	96	41	97	42
MMYEL	147	92	63%	104	-42	102	-45
OTHER	0	50		57	57	53	53
SXQOL	0	11		12	12	11	11
Total	3665	2148		2445	-1213	2498	-1167

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE
NON-THERAPEUTIC STUDIES ONLY (TXCA=N)
88% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2018 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2018 Accrual</u>	<u>Projected Increase <Decrease> from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase <Decrease> from Base</u>
	0	34		38	38	34	34
BREAST	37	285	770%	325	288	294	257
CCD	0	1293		1474	1474	1482	1482
GU	0	0		0	0	0	0
LEUK	69	14	20%	15	-53	14	-55
LUNG	43	566	1316%	645	602	625	582
LYMPH	53	0	0%	0	-53	0	-53
MMYEL	92	0	0%	0	-92	0	-92
OTHER	0	3		3	3	3	3
PREV	0	42		47	47	54	54
SURV	0	105		119	119	113	113
<u>SXQOL</u>	<u>878</u>	<u>4</u>	<u>0%</u>	<u>4</u>	<u>-873</u>	<u>4</u>	<u>-874</u>
Total	1172	2346		2670	1500	2623	1451

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE
ALL ACCRUAL REGISTRATIONS
88% of Calendar Year is Past

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2018 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2018 Accrual</u>	<u>Projected Increase <Decrease> from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase <Decrease> from Base</u>
	0	34		38	38	34	34
BREAST	1595	1076	67%	1227	-367	1194	-401
CCD	0	1293		1474	1474	1482	1482
ERLYTX	76	344	453%	392	316	455	379
GI	476	101	21%	115	-360	130	-346
GU	450	317	70%	361	-88	351	-99
GYN	57	0	0%	0	-57	0	-57
LEUK	219	131	60%	149	-69	135	-84
LUNG	567	781	138%	890	323	877	310
LYMPH	225	25	11%	28	-196	26	-199
MELAN	55	85	155%	96	41	97	42
MMYEL	239	92	38%	104	-134	102	-137
OTHER	0	53		60	60	56	56
PREV	0	42		47	47	54	54
SURV	0	105		119	119	113	113
SXQOL	878	15	2%	17	-860	15	-863
Total	4837	4494		5117	287	5121	284

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE
THERAPEUTIC REGISTRATIONS BY SWOG INSTITUTIONS ONLY (TXCA=Y)
88% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2018 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2018 Accrual</u>	<u>Projected Increase <Decrease> from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase <Decrease> from Base</u>
BREAST	1012	519	51%	591	-420	592	-420
ERLYTX	76	224	295%	255	179	296	220
GI	418	76	18%	86	-331	93	-325
GU	375	204	54%	232	-142	226	-149
GYN	57	0	0%	0	-57	0	-57
LEUK	122	80	66%	91	-30	84	-38
LUNG	441	171	39%	195	-245	197	-244
LYMPH	129	24	19%	27	-101	25	-104
MELAN	55	63	115%	71	16	73	18
MMYEL	85	85	100%	96	11	95	10
OTHER	0	50		57	57	53	53
SXQOL	0	11		12	12	11	11
Total	2770	1507		1713	-1051	1745	-1025

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE
NON-THERAPEUTIC STUDIES FOR SWOG INSTITUTIONS ONLY (TXCA=N)
88% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2018 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2018 Accrual</u>	<u>Projected Increase <Decrease> from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase <Decrease> from Base</u>
	0	34		38	38	34	34
BREAST	10	284	2840%	323	313	293	283
CCD	0	962		1097	1097	1087	1087
GU	0	0		0	0	0	0
LEUK	69	14	20%	15	-53	14	-55
LUNG	30	392	1307%	447	417	432	402
LYMPH	53	0	0%	0	-53	0	-53
MMYEL	92	0	0%	0	-92	0	-92
OTHER	0	3		3	3	3	3
PREV	0	27		30	30	35	35
SURV	0	69		78	78	75	75
<u>SXQOL</u>	<u>740</u>	<u>4</u>	<u>1%</u>	<u>4</u>	<u>-735</u>	<u>4</u>	<u>-736</u>
Total	994	1789		2035	1043	1977	983

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE
ALL ACCRUAL REGISTRATIONS BY SWOG INSTITUTIONS ONLY
88% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2018 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2018 Accrual</u>	<u>Projected Increase <Decrease> from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase <Decrease> from Base</u>
	0	34		38	38	34	34
BREAST	1022	803	79%	915	-106	885	-137
CCD	0	962		1097	1097	1087	1087
ERLYTX	76	224	295%	255	179	296	220
GI	418	76	18%	86	-331	93	-325
GU	375	204	54%	232	-142	226	-149
GYN	57	0	0%	0	-57	0	-57
LEUK	191	94	49%	107	-83	98	-93
LUNG	471	563	120%	642	171	629	158
LYMPH	182	24	13%	27	-154	25	-157
MELAN	55	63	115%	71	16	73	18
MMYEL	177	85	48%	96	-80	95	-82
OTHER	0	53		60	60	56	56
PREV	0	27		30	30	35	35
SURV	0	69		78	78	75	75
SXQOL	740	15	2%	17	-722	15	-725
Total	3764	3296		3751	-6	3722	-42

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE
ALL ACCRUAL REGISTRATIONS TO CANCER CONTROL STUDIES
88% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2018 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2018 Accrual</u>	<u>Projected Increase <Decrease> from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase <Decrease> from Base</u>
BREAST	65	678	1043%	773	708	763	698
CCD	0	1293		1474	1474	1482	1482
GI	81	40	49%	45	-35	44	-37
GU	215	193	90%	220	5	208	-7
LEUK	0	14		15	15	14	14
LUNG	53	25	47%	28	-24	33	-20
LYMPH	7	0	0%	0	-7	0	-7
MELAN	0	6		6	6	7	7
MMYEL	0	78		88	88	88	88
OTHER	0	6		6	6	6	6
PREV	0	42		47	47	54	54
SURV	0	105		119	119	113	113
SXQOL	878	15	2%	17	-860	15	-863
Total	1299	2495		2838	1542	2827	1528

16-NOV-2018 6:10
SWOG OPEN AND TEMPORARILY CLOSED STUDIES

Comm.	Phase	Study	Stat Center	Open Date	Months Open	Total Regs	Accrual Goal	Monthly Accrual Rate	Date of Expected Closure or Temporary Closure
		ACCL16N1	SWOG			34			
BREAST	II	NRGBR005 Br, Stg II&IIIA, Post NAdj Chemo Br Conserv	NRG	13APR2017:00:00:00		4		0.7	
		S1416 Brst, TNBC/BRCA, Cis+/- ABT-888	SWOG	07JUL2016:00:00:00	28	274	333	5.0	Oct-2019
		S1706 Breast, Inflammatory, RT +/- Olaparib	SWOG	12SEP2018:00:00:00	2	0	300		
	II-III	NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA	NRG	24DEC2014:00:00:00		1		0.0	
	III	A011106 Breast, Neoadj, ALTERNATE study	ALLIANCE	15FEB2014:00:00:00		80		3.8	
		A011401 Breast, adj, Stage II/III HER2-, weight loss	ALLIANCE	29AUG2016:00:00:00		191		9.0	
		A011502 Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo	ALLIANCE	08DEC2016:00:00:00		60		3.2	
		B51 Breast, Regional Nodal XRT	NRG	22AUG2013:00:00:00		32		1.2	
		B55 Brst, Adj Olaparib for BRCA, TNBC	NRG	03JUL2014:00:00:00		32		1.2	
		E2112 Brst,Adv,Exemestane+/-Entinostat	ECOG-ACRIN	02JAN2014:00:00:00		61		2.0	
		EA1151 Brst, Tomosynthesis Mammographic Screening	ECOG-ACRIN	06JUL2017:00:00:00		234		26.5	
		NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo	NRG	22JAN2015:00:00:00		66		1.8	
		S1207 Brst,Adj,Endocrine+/-Everolimus	SWOG	03SEP2013:00:00:00	62	1764	1900	28.0	Mar-2019
		S1222 Brst,Fulv. +/- Ever. +/- Anastr.	SWOG	09MAY2014:00:00:00		37	840		Feb-2015 Temp Close
		S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab)	SWOG	15NOV2016:00:00:00	24	298	1000	18.8	Dec-2021
	OTHER	A221405 Breast, ET interruption, Pregnancy Outcomes	ALLIANCE	15OCT2015:00:00:00		13		0.7	
		E1Z11 Brst,Genetic Predictors of AIMSS	ECOG-ACRIN	10MAY2013:00:00:00		156		1.0	
CCD	III	A011104 Preoperative Breast MRI	ALLIANCE	21FEB2014:00:00:00		19		0.8	
		A191402C PROS, Testing Decision Aids for Minority Men	ALLIANCE	14JUL2017:00:00:00		16		2.0	
		S1415CD TrACER CSF Standing Order Intervention for FN	SWOG	01SEP2016:00:00:00	26	2316	3960	93.5	Apr-2020
		S1703 Met Breast, STM-monitoring v Usual Care	SWOG	16JUL2018:00:00:00	4	1	1056	0.3	> 15 Yrs
	OTHER	EAQ162CD CCD, Financial Burden, Colon & Rectal Cancer	ECOG-ACR	17MAY2018:00:00:00		8		1.3	
		S1417CD Colorectal, Cost Cohort Study	SWOG	13MAY2016:00:00:00	30	336	374	15.2	Jan-2019
ERLYTX	II	A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib	ALLIANCE	06AUG2015:00:00:00		5		0.0	
		S1609 Rare Tumor, Comb Nivo/Ipi	SWOG	13JAN2017:00:00:00	22	539	707	7.8	Aug-2020
	II-III	A071102 GBM, adj TMZ +/- Veliparib	ALLIANCE	19SEP2014:00:00:00		49		1.2	
		ARST1321 NonRhabdo STS,Pazopanib (PAZNTIS)	COG	16MAY2014:00:00:00		9		0.2	
	OTHER	EAY131 MATCH	ECOG-ACRIN	12AUG2015:00:00:00		132		3.5	
GI	II	A021501 Adeno Panc,Borderline Resect,Chemo vs ChemoRT	ALLIANCE	01DEC2016:00:00:00		15		0.0	
		EA2142 GI NEC, Adv G3, EP vs TMZ + CAP	ECOG-ACRIN	06NOV2015:00:00:00		4		0.0	
		EA2161 PANC, Adv Rapalog Resistant PNETs, MLN0128	ECOG-ACR	01FEB2017:00:00:00		1		0.2	
		EA2165 Anal, Stg II-III, Nivolumab after CMT	ECOG-ACR	13APR2018:00:00:00		1		0.2	
		NRGGI002 Rectal, Ph II, Sensitization using TNT	NRG	12OCT2016:00:00:00		12		1.0	
		S1613 mCRC, Adv/Met, TP vs CETIRI	SWOG	09OCT2017:00:00:00	13	11	130	1.3	Apr-2026

16-NOV-2018 6:10
SWOG OPEN AND TEMPORARILY CLOSED STUDIES

Comm.	Phase	Study	Stat Center	Open Date	Months Open	Total Regs	Accrual Goal	Monthly Accrual Rate	Date of Expected Closure or Temporary Closure
	II-III	N1048 Rectal,LocalAdv,ChemoRT+/-FOLFOX	ALLIANCE	13JAN2012:00:00:00		165		2.7	
	III	A021502 Colon, Stg III, Chemo +/- Atezol, ATOMIC	ALLIANCE	12SEP2017:00:00:00		7		0.8	
		NRGGI004 Colorectal, Stg IV, dMMR Immuno-Therapy	NRG	07NOV2017:00:00:00		4		0.5	
GU	II	EA8153 Pros, ADT + Abira +/- Cabazitaxel (CHAARTED2)	ECOG-ACR	08FEB2018:00:00:00		2		0.3	
		S1500 pRCC,Adv, Sunitinib vs MET inhib	SWOG	05APR2016:00:00:00	31	114	180	5.2	Nov-2019
		S1605 Blad, BCG-Unresponsive NMIBC, Atezolizumab	SWOG	07FEB2017:00:00:00	21	99	148	8.8	Apr-2019
	II-III	NRGGU002 Pros, RT + ADT After RP +/- Adj Docetaxel	NRG	30DEC2016:00:00:00		1		0.0	
	III	A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE)	ALLIANCE	01JUL2015:00:00:00		4		0.2	
		A031501 Bladder, MIBC/Loc Adv, Adjv Pembro vs Obs	ALLIANCE	21SEP2017:00:00:00		10		1.7	
		EA8143 RCC, HR, Surg +/- Nivolumab (PROSPER)	ECOG-ACRIN	02FEB2017:00:00:00		18		1.2	
		R0924 Pros, NADT+WPRT vs. NADT+P&SV RT	NRG	07JUL2011:00:00:00		90		2.5	
		S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG	SWOG	07FEB2017:00:00:00	21	182	969	13.3	Oct-2023
		S1802 Pros, Stg IV, SST +/- Surg/RT to Primary Tum	SWOG	17SEP2018:00:00:00	1	16	1273		
LEUK	I	S1312 ALL, CD22+, REL/REF, Inotuzumab+CVP	SWOG	01APR2014:00:00:00	55	45	38	1.2	Jun-2018
	I-II	S1318 ALL, Age 65+, Ph±, Blinatumomab	SWOG	12JAN2015:00:00:00		47	44		Sep-2017 Temp Close
	II	S1712 CML, chronic phase, TKI +/- Ruxolitinib	SWOG	20JUL2018:00:00:00	3	1	84	0.3	> 15 Yrs
	II-III	S1612 AML/MDS, Age 60+, Aza/Novel Therapeutics	SWOG	22DEC2017:00:00:00		78	1670		Temp Close
	III	E1910 BCR-ABL-neg, B ALL, Blinatumomab	ECOG-ACRIN	23DEC2013:00:00:00		101		3.0	
		E2906 AML, Age 60+, Clo vs Dauno+Cy	ECOG-ACRIN	24FEB2011:00:00:00		75		0.0	
	OTHER	NHLBIMDS LEUK, National MDS Study	ECOG-ACRIN	05APR2016:00:00:00		19		1.3	
LUNG	II	EA5161 Lung, ED-SCLC, Cis/Carbo and Eto +/- Nivo	ECOG-ACRIN	02MAY2018:00:00:00		14		2.3	
		S1400F Non-Match: MEDI4736 + Tremelimumab	SWOG	02OCT2017:00:00:00	13	44	132	4.5	Jun-2020
		S1400K c-Met: ABBV-399 (Process II)	SWOG	05FEB2018:00:00:00		28	44		Oct-2018 Temp Close
		S1701 Thymic Adv, Carbo/Pac/Ram vs. Carbo/Pac	SWOG	09AUG2018:00:00:00	3	0	66	0.0	> 15 Yrs
	II-III	NRGCC003 SCLC, PCI or HA-PCI	NRG	07DEC2015:00:00:00		4		0.0	
	III	A081105 ALCHEMIST1, EGFR mut, Erlotinib	ALLIANCE	02JAN2014:00:00:00		43		0.7	
		C30610 SCLC, Thoracic RT	ALLIANCE	21MAR2008:00:00:00		56		0.0	
		E4512 ALCHEMIST2, ALK mut, Crizotinib	ECOG-ACRIN	18AUG2014:00:00:00		10		0.3	
		EA5142 ALCHEMIST3, Non-match, Nivolumab	ECOG-ACRIN	16MAY2016:00:00:00		76		5.0	
	OTHER	A151216 ALCHEMIST0 - screening	ALLIANCE	06FEB2014:00:00:00		619		19.3	
		S1400 SCCA,Adv, Biomarker Master	SWOG	15JUN2014:00:00:00	53	1832		32.3	
	PILOT	S1619 Meso,Stg I-III, Nadj chemo/Atezmb->Atezmb+SOC	SWOG	03NOV2017:00:00:00	12	6	28	1.0	Sep-2020
LYMPH	II	S1608 FL, TGR-1202/Lenalidomide/CHOP or Benda +Ob	SWOG	10AUG2017:00:00:00	15	10	150	1.0	Jun-2030
	III	A051301 ABC DLBCL, Auto HCT and Ibrutinib/Placebo	ALLIANCE	15JUL2016:00:00:00		6		0.0	
		EA4151 Lymph, AHCT +/-Ritux, MRD Neg	ECOG-ACRIN	29AUG2017:00:00:00		14		1.8	

SWOG OPEN AND TEMPORARILY CLOSED STUDIES

Comm.	Phase	Study	Stat Center	Open Date	Months Open	Total Regs	Accrual Goal	Monthly Accrual Rate	Date of Expected Closure or Temporary Closure
MELAN	II	S1320 Adv, BRAF mut, Inter v Contin	SWOG	22JUL2014:00:00:00	51	229	280	2.3	Aug-2020
		S1512 Melan, Adv, Desmoplastic, MK-3475 (pembro)	SWOG	20OCT2016:00:00:00	24	17	77	1.2	Feb-2023
		S1607 MELAN, Adv, T-VEC, MK-3475	SWOG	02OCT2017:00:00:00	13	7	64	1.2	Nov-2022
		S1616 MELAN, Adv, Ipilimumab ± Nivolumab	SWOG	17JUL2017:00:00:00	15	26	94	2.7	Dec-2020
	II-III	EA6141 Melan, Avd, Nivolumab+Ipi ± Sargmostim	ECOG-ACRIN	01MAR2016:00:00:00		36		0.0	
	III	EA6134 Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T	ECOG-ACRIN	15DEC2015:00:00:00		30		0.7	
MMYEL	II	S1702 AL Amyloidosis, Relapsed, Isatuximab	SWOG	08MAR2018:00:00:00	8	14	39	2.3	Sep-2019
	III	E1A11 MM, frontline, BLD vs CLD	ECOG-ACRIN	22NOV2013:00:00:00		236		5.3	
OTHER	I-II	A091304 Adv Sarc, MLN0128 v Pazopanib, Phi/II	ALLIANCE	26JAN2015:00:00:00		35		2.8	
		A091305 HN, Adv, Thyroid PPAR agonist + Chemo	ALLIANCE	01SEP2014:00:00:00		2		0.0	
		A091401 Sarc,	ALLIANCE	18JUN2015:00:00:00		10		0.5	
		A091404 HN, AR+, Enzalutamide	ALLIANCE	25SEP2015:00:00:00		9		0.2	
		EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp	ECOG-ACRIN	29MAR2016:00:00:00		11		0.8	
		EAF151 Brain, GBM, Bev, Blood Volume	ECOG-ACRIN	14APR2017:00:00:00		2		0.2	
		NRGBN001 HN, novel vs. std chemoradiation + chemo	NRG	28AUG2015:00:00:00		1		0.0	
	II-III	NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care	NRG	06FEB2016:00:00:00		3		0.0	
		NRGGY009 Ovar, PLD/Atexo vs PLD/Atezo/Bev vs PLD/Bev	NRG	12MAY2017:00:00:00		2		0.3	
		NRGHN001 Nasopharyngeal , Individual Tx EBV	NRG	21APR2014:00:00:00		5		0.2	
		R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux	NRG	18MAR2013:00:00:00		3		0.0	
	III	G0263 Cerv, Stg I/IIA, adjv RT vs chemoRT	NRG	12APR2010:00:00:00		1		0.0	
		N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC	ALLIANCE	22SEP2009:00:00:00		7		0.2	
		R0724 Cervical, Chem+RT +/- Adj. Chemo	NRG	15JAN2014:00:00:00		1		0.0	
		OTHER	EAQ152 Communication & education in tumor profiling	ECOG-ACRIN	26SEP2016:00:00:00		14		0.5
PREV	III	A211102 Breast, Atypia via RPFNA, Metformin v Placebo	ALLIANCE	01FEB2015:00:00:00		3		0.0	
		S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac	SWOG	01MAR2013:00:00:00	68	218	480	4.2	Jan-2024
SURV	III	E1Q11 EROS: Reproductive Health in Cancer Survivors	ECOG-ACRIN	30SEP2015:00:00:00		18		1.3	
		S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol	SWOG	15SEP2017:00:00:00	14	48	817	6.7	Jun-2028
	OTHER	EA9131 Leuk, Strategy to decrease early APL deaths	ECOG-ACRIN	16AUG2017:00:00:00		13		0.8	
	S1316 Compar. Effectiv. Trial for MBO	SWOG	01AUG2014:00:00:00	51	168	200	2.2	Jan-2020	
SXQOL	III	A221101 Glioma, Nuvigil/Placebo Fatigue	ALLIANCE	03JUN2013:00:00:00		21		0.2	
		A221505 Brst, Hypofractionated Post Mast Rad	ALLIANCE	01FEB2018:00:00:00		5		0.8	

SWOG OPEN AND TEMPORARILY CLOSED STUDIES

Comm.	Phase	Study	Stat Center	Open Date	Months Open	Total Regs	Accrual Goal	Monthly Accrual Rate	Date of Expected Closure or Temporary Closure
		NRGGU003 Pros, Post-Prostatectomy HYPOR vs COPORT NRG		28JUL2017:00:00:00		6		0.8	

Accrual goals assume studies are not terminated early as a result of interim analysis.
 Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
 Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
 Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.

OPEN AND TEMPORARILY CLOSED STUDIES: BY STUDY TYPE, COMMITTEE, INTERGROUP, SWOG/OTHER STAT CENTER

Phase	Comm.	Int grp	Stat Center	Study	NCIPROTO	CA Cntrl Study	Temp Close
OTHER	BREAST	Y	ECOG-ACRIN	E1Z11 Brst,Genetic Predictors of AIMSS	E1Z11	Y	
		Y	ALLIANCE	A221405 Breast, ET interruption, Pregnancy Outcomes	A221405	Y	
	CCD	N		S1417CD Colorectal, Cost Cohort Study		Y	
		Y	ECOG-ACR	EAQ162CD CCD, Financial Burden, Colon & Rectal Cancer	EAQ162CD	Y	
	ERLYTX	Y	ECOG-ACRIN	EAY131 MATCH	EAY131	N	
	LEUK	Y	ECOG-ACRIN	NHLBIMDS LEUK, National MDS Study	NHLBI-MDS	Y	
	LUNG	Y	SWOG	S1400 SCCA,Adv, Biomarker Master	S1400	N	
		Y	ALLIANCE	A151216 ALCHEMIST0 - screening	A151216	N	
	OTHER	Y	ECOG-ACRIN	EAQ152 Communication & education in tumor profiling	EAQ152	Y	
	SURV	Y	SWOG	S1316 Compar. Effectiv. Trial for MBO	S1316	Y	
		Y	ECOG-ACRIN	EA9131 Leuk, Strategy to decrease early APL deaths	EA9131	Y	
I	LEUK	N		S1312 ALL, CD22+, REL/REF, Inotuzumab+CVP		N	
I-II	LEUK	Y	SWOG	S1318 ALL, Age 65+, Ph±, Blinatumomab	S1318	N	Y
	OTHER	Y	ALLIANCE	A091304 Adv Sarc, MLN0128 v Pazopanib, Phi/II	A091304	N	
II	BREAST	Y	SWOG	S1416 Brst, TNBC/BRCA, Cis+/- ABT-888	S1416	N	
		Y	SWOG	S1706 Breast, Inflammatory, RT +/- Olaparib	S1706	N	
		Y	NRG	NRGBR005 Br, Stg II&IIIA, Post NAdj Chemo Br Conserv	NRG-BR005	N	
	ERLYTX	Y	SWOG	S1609 Rare Tumor, Comb Nivo/Ipi	S1609	N	
		Y	ALLIANCE	A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib	A071401	N	
	GI	Y	SWOG	S1613 mCRC, Adv/Met, TP vs CETIRI	S1613	N	
		Y	ECOG-ACR	EA2161 PANC, Adv Rapalog Resistant PNETs, MLN0128	EA2161	N	
		Y	ECOG-ACRIN	EA2142 GI NEC, Adv G3, EP vs TMZ + CAP	EA2142	N	
		Y	ECOG-ACR	EA2165 Anal, Stg II-III, Nivolumab after CMT	EA2165	N	
		Y	NRG	NRGGI002 Rectal, Ph II, Sensitization using TNT	NRG-GI002	N	
		Y	ALLIANCE	A021501 Adeno Panc,Borderline Resect,Chemo vs ChemoRT	A021501	N	
	GU	Y	SWOG	S1500 pRCC,Adv, Sunitinib vs MET inhib	S1500	N	
		Y	SWOG	S1605 Blad, BCG-Unresponsive NMIBC, Atezolizumab	S1605	N	
		Y	ECOG-ACR	EA8153 Pros, ADT + Abira +/- Cabazitaxel (CHAARTED2)	EA8153	N	
	LEUK	Y	SWOG	S1712 CML, chronic phase, TKI +/- Ruxolitinib	S1712	N	
	LUNG	Y	SWOG	S1400K c-Met: ABBV-399 (Process II)	S1400K	N	Y
		Y	SWOG	S1400F Non-Match: MEDI4736 + Tremelimumab	S1400F	N	
		Y	SWOG	S1701 Thymic Adv, Carbo/Pac/Ram vs. Carbo/Pac	S1701	N	
		Y	ECOG-ACRIN	EA5161 Lung, ED-SCLC, Cis/Carbo and Eto +/- Nivo	EA5161	N	
	LYMPH	Y	SWOG	S1608 FL, TGR-1202/Lenalidomide/CHOP or Benda +Ob	S1608	N	
	MELAN	Y	SWOG	S1320 Adv, BRAF mut, Inter v Contin	S1320	N	
		Y	SWOG	S1607 MELAN, Adv, T-VEC, MK-3475	S1607	N	
		Y	SWOG	S1616 MELAN, Adv, Ipilimumab ± Nivolumab	S1616	N	

OPEN AND TEMPORARILY CLOSED STUDIES: BY STUDY TYPE, COMMITTEE, INTERGROUP, SWOG/OTHER STAT CENTER

Phase	Comm.	Int grp	Stat Center	Study	NCIPROTO	CA Cntrl Study	Temp Close
		Y	SWOG	S1512 Melan, Adv, Desmoplastic, MK-3475 (pembro)	S1512	N	
	MMYEL	Y	SWOG	S1702 AL Amyloidosis, Relapsed, Isatuximab	S1702	N	
	OTHER	Y	NRG	NRGBN001 HN, novel vs. std chemoradiation + chemo	NRG-BN001	N	
		Y	ALLIANCE	A091401 Sarc,	A091401	N	
		Y	ALLIANCE	A091305 HN, Adv, Thyroid PPAR agonist + Chemo	A091305	N	
		Y	ALLIANCE	A091404 HN, AR+, Enzalutamide	A091404	N	
		Y	ECOG-ACRIN	EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp	EA3132	N	
		Y	ECOG-ACRIN	EAF151 Brain, GBM, Bev, Blood Volume	EAF151	N	
PILOT	LUNG	Y	SWOG	S1619 Meso,Stg I-III, Nadj chemo/Atezmb->Atezmb+SOC	S1619	N	
II-III	BREAST	Y	NRG	NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA	NRG-BR002	N	
	ERLYTX	Y	ALLIANCE	A071102 GBM, adj TMZ +/- Veliparib	A071102	N	
		Y	COG	ARST1321 NonRhabdo STS,Pazopanib (PAZNTIS)	ARST1321	N	
	GI	Y	ALLIANCE	N1048 Rectal,LocalAdv,ChemoRT+/-FOLFOX	N1048	Y	
	GU	Y	NRG	NRGGU002 Pros, RT + ADT After RP +/- Adj Docetaxel	NRG-GU002	N	
	LEUK	Y	SWOG	S1612 AML/MDS, Age 60+, Aza/Novel Therapeutics	S1612	N	Y
	LUNG	Y	NRG	NRGCC003 SCLC, PCI or HA-PCI	NRG-CC003	Y	
	MELAN	Y	ECOG-ACRIN	EA6141 Melan, Avd, Nivolumab+Ipi ± Sargmostim	EA6141	N	
	OTHER	Y	NRG	NRGGY009 Ovar, PLD/Atezo vs PLD/Atezo/Bev vs PLD/Bev	NRG-GY009	Y	
		Y	NRG	NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care	NRG-GY005	Y	
		Y	NRG	R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux	RTOG-1216	Y	
		Y	NRG	NRGHN001 Nasopharyngeal , Individual Tx EBV	NRG-HN001	Y	
III	BREAST	N		S1222 Brst,Fulv. +/- Ever. +/- Anastr.		N	Y
		Y	SWOG	S1207 Brst,Adj,Endocrine+/-Everolimus	S1207	Y	
		Y	SWOG	S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab)	S1418	Y	
		Y	ALLIANCE	A011106 Breast, Neoadj, ALTERNATE study	A011106	N	
		Y	NRG	B51 Breast, Regional Nodal XRT	NSABP-B-51	Y	
		Y	ALLIANCE	A011401 Breast, adj, Stage II/III HER2-, weight loss	A011401	Y	
		Y	NRG	NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo	NRG-BR003	N	
		Y	ECOG-ACRIN	E2112 Brst,Adv,Exemestane+/-Entinostat	E2112	Y	
		Y	ALLIANCE	A011502 Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo	A011502	Y	
		Y	ECOG-ACRIN	EA1151 Brst, Tomosynthesis Mammographic Screening	EA1151	N	
		Y	NRG	B55 Brst, Adj Olaparib for BRCA,TNBC	NSABP-B-55	Y	
	CCD	Y	SWOG	S1415CD TrACER CSF Standing Order Intervention for FN	S1415CD	Y	
		Y	SWOG	S1703 Met Breast, STM-monitoring v Usual Care	S1703	Y	
		Y	ALLIANCE	A011104 Preoperative Breast MRI	A011104	Y	
		Y	ALLIANCE	A191402C PROS, Testing Decision Aids for Minority Men	A191402CD	Y	
	GI	Y	ALLIANCE	A021502 Colon, Stg III, Chemo +/- Atezol, ATOMIC	A021502	Y	

OPEN AND TEMPORARILY CLOSED STUDIES: BY STUDY TYPE, COMMITTEE, INTERGROUP, SWOG/OTHER STAT CENTER

Phase	Comm.	Int grp	Stat Center	Study	NCIPROTO	CA Cntrl Study	Temp Close
		Y	NRG	NRGGI004 Colorectal, Stg IV, dMMR Immuno-Therapy	NRG-GI004	Y	
GU		Y	SWOG	S1802 Pros, Stg IV, SST +/- Surg/RT to Primary Tum	S1802	Y	
		Y	SWOG	S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG	S1602	Y	
		Y	NRG	R0924 Pros, NADT+WPRT vs. NADT+P&SV RT	RTOG-0924	Y	
		Y	ECOG-ACRIN	EA8143 RCC, HR, Surg +/- Nivolumab (PROSPER)	EA8143	Y	
		Y	ALLIANCE	A031501 Bladder, MIBC/Loc Adv, Adjv Pembro vs Obs	A031501	Y	
		Y	ALLIANCE	A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE)	A031102	Y	
LEUK		Y	ECOG-ACRIN	E2906 AML, Age 60+, Clo vs Dauno+Cy	E2906	Y	
		Y	ECOG-ACRIN	E1910 BCR-ABL-neg, B ALL, Blinatumomab	E1910	N	
LUNG		Y	ALLIANCE	C30610 SCLC, Thoracic RT	CALGB-30610	Y	
		Y	ALLIANCE	A081105 ALCHEMIST1, EGFR mut, Erlotinib	A081105	N	
		Y	ECOG-ACRIN	EA5142 ALCHEMIST3, Non-match, Nivolumab	EA5142	N	
		Y	ECOG-ACRIN	E4512 ALCHEMIST2, ALK mut, Crizotinib	E4512	N	
LYMPH		Y	ECOG-ACRIN	EA4151 Lymph, AHCT +/-Ritux, MRD Neg	EA4151	N	
		Y	ALLIANCE	A051301 ABC DLBCL, Auto HCT and Ibrutinib/Placebo	A051301	N	
MELAN		Y	ECOG-ACRIN	EA6134 Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T	EA6134	Y	
MMYEL		Y	ECOG-ACRIN	E1A11 MM, frontline, BLD vs CLD	E1A11	Y	
OTHER		Y	ALLIANCE	N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC	N0577	N	
		Y	NRG	G0263 Cerv, Stg I/IIA, adjv RT vs chemoRT	GOG-0263	Y	
		Y	NRG	R0724 Cervical, Chem+RT +/- Adj. Chemo	RTOG-0724	Y	
PREV		Y	SWOG	S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac	S0820	Y	
		Y	ALLIANCE	A211102 Breast, Atypia via RPFNA, Metformin v Placebo	A211102	Y	
SURV		Y	SWOG	S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol	S1501	Y	
		Y	ECOG-ACRIN	E1Q11 EROS: Reproductive Health in Cancer Survivors	E1Q11	Y	
SXQOL		Y	ALLIANCE	A221101 Glioma, Nuvigil/Placebo Fatigue	A221101	Y	
		Y	ALLIANCE	A221505 Brst, Hypofractionated Post Mast Rad	A221505	Y	
		Y	NRG	NRGGU003 Pros, Post-Prostatectomy HYPOR vs COPORT	NRG-GU003	Y	
		Y		ACCL16N1	ACCL16N1CD		